Core Viewpoint - Meiz Health (02415) reported a significant increase in both revenue and net profit for the first half of 2025, driven by the recovery in the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models [1] Financial Performance - Revenue reached 125 million RMB, representing a year-on-year growth of 13.2% [1] - Net profit amounted to 13.239 million RMB, showing a remarkable year-on-year increase of 5238.3% [1] - Basic earnings per share were 2.45 cents, with a proposed interim dividend of 1.1 Hong Kong cents per share [1] Industry Trends - The growth in total revenue is attributed to the recovery in the pharmaceutical sector [1] - There is an increasing demand for precision omnichannel marketing solutions, driven by the transformation of domestic pharmaceutical companies [1]
梅斯健康(02415)发布中期业绩，净利润1323.9万元，同比增长5238.3%